Updating results

42 results

Sort: Relevance | Date

Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

Summary of the evidence on ceftazidime/avibactam for complicated intra-abdominal and UTI infections and hospital-acquired pneumonia

Evidence summary: antimicrobial prescribing Published November 2017

Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

ES12 Non-cystic fibrosis bronchiectasis: inhaled tobramycin Key points

Evidence summary Published April 2017

Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

Summary of the evidence on colistimethate sodium (Colobreathe) for non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published January 2014

Gastroparesis in adults: oral erythromycin (ESUOM13)

Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

Evidence summary Published June 2013

Difficult-to-treat scabies: oral ivermectin (ESUOM29)

Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making

Evidence summary Published March 2014

Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)

Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

Evidence summary Published January 2016

Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)

Summary of the evidence on Truvada (emtricitabine/tenofovir disoproxil) for pre-exposure prophylaxis (PrEP) of HIV in adults at high risk

Evidence summary Published October 2016

Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making

Evidence summary Published June 2016

Cystic fibrosis: long-term azithromycin (ESUOM37)

Summary of the evidence on long-term azithromycinoral for treating cystic fibrosis (CF) to inform local NHS planning and decision-making

Evidence summary Published November 2014

Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

Summary of the evidence on long-term azithromycin for treating non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published November 2014

Pouchitis: rifaximin (ESUOM30)

Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

Evidence summary Published March 2014

Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

Evidence summary Published March 2015

Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)

Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making

Evidence summary Published March 2016

External genital and perianal warts: green tea (Camellia sinensis) leaf extract 10% ointment (ESNM66)

Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning

Evidence summary Published December 2015

Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

Summary of the evidence on telavancin (Vibativ) for hospital-acquired pneumonia caused by MRSA to inform local NHS planning and decision-making

Evidence summary Published July 2014

Clostridium difficile infection: fidaxomicin (ESNM1)

Summary of the evidence on fidaxomicin for treating Clostridium difficile (C. diff/C. difficile) infection to inform local NHS planning and decision-making

Evidence summary Published July 2012

Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide (KTT24)

KTT24 Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide Key points

Key therapeutic topic Published March 2019 Last updated September 2019

Shared decision making (KTT23)

KTT23 Shared decision making Key points In the context of medicines optimisation, shared

Key therapeutic topic Published March 2019 Last updated September 2019

Omega-3 fatty acid supplements (KTT4)

KTT4 KTT4

Key therapeutic topic Published January 2015

Three-day courses of antibiotics for uncomplicated urinary tract infection (KTT10)

KTT10 KTT10

Key therapeutic topic Published January 2015 Last updated February 2016

Chemotherapy dose standardisation (KTT22)

KTT22 Chemotherapy dose standardisation Key points Chemotherapy dose standardisation

Key therapeutic topic Published February 2018 Last updated September 2019

Antimicrobial stewardship: prescribing antibiotics (KTT9)

KTT9 Antimicrobial stewardship: prescribing antibiotics Key points Antimicrobial resistance

Key therapeutic topic Published January 2015 Last updated September 2019

Type 2 diabetes mellitus: medicines optimisation priorities (KTT12)

KTT12 Type 2 diabetes mellitus: medicines optimisation priorities Key points The NICE

Key therapeutic topic Published January 2015 Last updated September 2019

Biosimilar medicines (KTT15)

KTT15 Biosimilar medicines Options for local implementation Biosimilar medicines have

Key therapeutic topic Published February 2016 Last updated February 2018

Multimorbidity and polypharmacy (KTT18)

KTT18 Multimorbidity and polypharmacy Key points Multimorbidity is associated with

Key therapeutic topic Published January 2017 Last updated September 2019

Renin-angiotensin system drugs: dual therapy (KTT2)

KTT2 Renin-angiotensin system drugs: dual therapy Options for local implementation Dual

Key therapeutic topic Published January 2015 Last updated February 2016

Asthma: medicines safety priorities (KTT5)

KTT5 Asthma: medicines safety priorities Key points Inhaled corticosteroids (ICS) are

Key therapeutic topic Published January 2015 Last updated September 2019

First-choice antidepressant use in adults with depression or generalised anxiety disorder (KTT8)

KTT8 First-choice antidepressant use in adults with depression or generalised anxiety disorder Options for local implementation

Key therapeutic topic Published January 2015 Last updated February 2016

Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)

KTT16 Anticoagulants, including direct-acting oral anticoagulants (DOACs) Key points

Key therapeutic topic Published February 2016 Last updated September 2019

Lipid-modifying drugs (KTT3)

KTT3 Lipid-modifying drugs Key points The NICE guideline on cardiovascular disease:

Key therapeutic topic Published January 2015 Last updated September 2019

Antipsychotics in people living with dementia (KTT7)

KTT7 Antipsychotics in people living with dementia Key points The risks and limited

Key therapeutic topic Published January 2015 Last updated September 2019

Wound care products (KTT14)

KTT14 Wound care products Key points A large number of wound dressings are available

Key therapeutic topic Published January 2015 Last updated September 2019

Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI (KTT17)

KTT17 Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI Key points

Key therapeutic topic Published February 2016 Last updated September 2019

Hypnotics (KTT6)

KTT6 Hypnotics Key points The risks associated with hypnotics (including melatonin)

Key therapeutic topic Published January 2015 Last updated September 2019

Minocycline (KTT11)

KTT11 Minocycline Options for local implementation Review and, if appropriate, revise

Key therapeutic topic Published January 2015

Psychotropic medicines in people with learning disabilities whose behaviour challenges (KTT19)

KTT19 Psychotropic medicines in people with learning disabilities whose behaviour challenges Key points

Key therapeutic topic Published January 2017 Last updated September 2019

Non-steroidal anti-inflammatory drugs (KTT13)

KTT13 Non-steroidal anti-inflammatory drugs Options for local implementation Review

Key therapeutic topic Published January 2015 Last updated February 2018

Laxatives (KTT1)

KTT1 Laxatives Options for local implementation Review and, if appropriate, revise prescribing

Key therapeutic topic Published January 2015

Safer insulin prescribing (KTT20)

KTT20 Safer insulin prescribing Key points Several new insulin products have been launched

Key therapeutic topic Published January 2017 Last updated September 2019

Medicines optimisation in chronic pain (KTT21)

KTT21 Medicines optimisation in chronic pain Key points Controlling chronic pain can

Key therapeutic topic Published January 2017 Last updated September 2019

Multidrug resistant urinary tract infections: fosfomycin trometamol (ESUOM17)

This evidence summary has been withdrawn because a product containing fosfomycin trometamol with a marketing authorisation for treating multidrug resistant urinary tract infections is now available in the UK.

Evidence summary Published July 2013